NeurAegis Inc. With a focus on traumatic brain injury (TBI)/concussion and epilepsy, NeurAegis aims to address critical unmet medical needs in the field. One of their key areas of expertise lies in the development of novel protease inhibitors, which are considered first-in-class compounds for treating various neurological disorders.

In particular, NeurAegis is dedicated to advancing treatments for TBI/concussion, a significant public health concern in the United States. Their research is crucial, as there are currently no FDA-approved medications specifically designed to address the neuronal damage and death that occurs after such injuries. With over 3.

8 million reported sports- and recreation-related concussions in the US each year, NeurAegis recognizes the importance of their innovative solutions. With an impressive track record and a team of experienced experts, NeurAegis has been making significant strides in the field. The company has been awarded a $3.

8 million grant from the Department of Defense, demonstrating their commitment to providing effective concussion therapy. Moreover, their strong intellectual property and extensive portfolio position them at the forefront of the industry. Stay updated with NeurAegis through their recent news, showcasing their achievements and collaborations.

From being featured in Pharmaceutical Technology to receiving additional award funding, NeurAegis is consistently progressing in their mission to improve neurological treatments. Contact NeurAegis today to learn more about their pioneering research and game-changing contributions to the field of neuropharmaceuticals